Drugs / incabotulinumtoxinA
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01968902 Comparator | Nov 2013 → Jan 2016 | multiple sclerosis | Multiple Sclerosis Center of Northeastern New York | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | incabotulinumtoxinA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01968902 ↗ |
| Action | Inhibit | “The results suggest that botulinum A toxin, an inhibitor of acetylcholine release at the neuromuscular junction, may be useful in the treatment of detrusor-sphincter dyssynergia.” PMID 2297305 ↗ Jan 1990 |
| Modality | Protein / enzyme biologic | “Botulinum toxin type A (BTX), a neuromuscular blocking agent” PMID 10641699 ↗ Jan 2000 |
| Route | Intramuscular | “intramuscular injection, 200 to 400 units, 1 injection visit only” NCT01968902 ↗ |